Evidence map›Paper›PMID 32157212›Full record

ArticleOncogene2020

Tumor progression and chromatin landscape of lung cancer are regulated by the lineage factor GATA6.

Anna Arnal-Estapé, Wesley L Cai, Alexandra E Albert, Minghui Zhao, Laura E Stevens, Francesc López-Giráldez, Kiran D Patel, Siddhartha Tyagi, Earlene M Schmitt, Thomas F Westbrook and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Oncogene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Cancer discovery · 2022
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Anna Arnal-EstapéDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-0490-7040
Wesley L CaiDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Alexandra E AlbertDepartment of Cell Biology, Yale University School of Medicine, New Haven, CT, USA.
Minghui ZhaoDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Laura E StevensDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Francesc López-GiráldezYale Center for Genome Analysis, Yale University School of Medicine, New Haven, CT, USA.
Kiran D PatelDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Siddhartha TyagiDepartment of Biochemistry & Molecular Biology, Baylor College of Medicine, Houston, TX, USA.
Earlene M SchmittDepartment of Biochemistry & Molecular Biology, Baylor College of Medicine, Houston, TX, USA.
Thomas F WestbrookDepartment of Biochemistry & Molecular Biology, Baylor College of Medicine, Houston, TX, USA.
Don X NguyenDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA. don.nguyen@yale.edu.
Yale University · USBaylor College of Medicine · USYale Cancer Center · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007205 · NIGMS · YALE UNIVERSITY · PI KAZMIERCZAK, BARBARA I · 1985 to 2019
$42.9M
A Novel Lineage Specific Metastasis Suppressor Pathway in Lung CancerR01CA166376 · NCI · YALE UNIVERSITY · PI NGUYEN, DON X · 2012 to 2024
$3.8M
Yale Cancer Biology Training GrantT32CA193200 · NCI · YALE UNIVERSITY · PI PETER M GLAZER, Qin Yan · 2016 to 2026
$3.6M
A novel lineage pathway controls metabolic adaptation by metastatic lung cancersR01CA191489 · NCI · YALE UNIVERSITY · PI NGUYEN, DON X · 2015 to 2019
$1.9M
Discovering genetic networks of triple-negative breast cancerR01CA178039 · NCI · BAYLOR COLLEGE OF MEDICINE · PI WESTBROOK, THOMAS · 2013 to 2017
$1.6M
NCI NIH HHS R01 CA166376NCI NIH HHS R01 CA178039NCI NIH HHS R01 CA191489NCI NIH HHS T32 CA193200NIGMS NIH HHS T32 GM007205
6 · The paper itself

Abstract

Lineage selective transcription factors (TFs) are important regulators of tumorigenesis, but their biological functions are often context dependent with undefined epigenetic mechanisms of action. In this study, we uncover a conditional role for the endodermal and pulmonary specifying TF GATA6 in lung adenocarcinoma (LUAD) progression. Impairing Gata6 in genetically engineered mouse models reduces the proliferation and increases the differentiation of Kras mutant LUAD tumors. These effects are influenced by the epithelial cell type that is targeted for transformation and genetic context of Kras-mediated tumor initiation. In LUAD cells derived from surfactant protein C expressing progenitors, we identify multiple genomic loci that are bound by GATA6. Moreover, suppression of Gata6 in these cells significantly alters chromatin accessibility, particularly at distal enhancer elements. Analogous to its paradoxical activity in lung development, GATA6 expression fluctuates during different stages of LUAD progression and can epigenetically control diverse transcriptional programs associated with bone morphogenetic protein signaling, alveolar specification, and tumor suppression. These findings reveal how GATA6 can modulate the chromatin landscape of lung cancer cells to control their proliferation and divergent lineage dependencies during tumor progression.

Indexed as

Adenocarcinoma of LungAnimalsCarcinogenesisCell DifferentiationCell LineageCell ProliferationChromatinDisease Models, AnimalGATA6 Transcription FactorGene Expression Regulation, NeoplasticHumansLungLung NeoplasmsMiceProto-Oncogene Proteins p21(ras)ChromatinGata6 protein, mouseGATA6 Transcription FactorHras protein, mouseProto-Oncogene Proteins p21(ras)

Identifiers

PMID32157212
PMCPMC7190573
OpenAlexW3011780377

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.